Jenny: Okay, so in the evolution, it sounds like you're combining the flow cytometry with the PCR test, which I understand are the gene expression profiling tests. Is that correct?
Dr. Paiva: Indeed. And again, emphasizing that the follow-up of the study still need time, so definitely more mature data will be needed to really make a final statement on that particular analysis, but yes, this trial is very, very safe. Other clinical trials are really showing that the outcome between high-risk and standard risk patients -- well, the poor outcome of high-risk patients is not yet fully overcome, but it is being ameliorated. This means that -- and this is my personal point of view, that as therapy becomes more and more effective, the way we call high-risk now may be different from the way we will call high-risk in the future, plus this will also mean that perhaps -- and everything is complementary, but perhaps more important is risk stratification of diagnosis because therapy has become so much effective, but perhaps more important than that would be really a sensitive monitoring of this positive therapy. To make a final argument on your question and again, really sending the message that as we move along very slowly, as it needs to be done, we cannot rush into precision medicine.
Gary: Okay. This is kind of the clincher question. Of the high-risk patients that have achieved MRD negative status, is there a treatment plan which has the best outcomes?
Become a sponsor today and get a SWORD avatar next to your name in chat that levels up as your membership ages, PLUS my ...
Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
An informational guide to sauce up your play on the new legend 'Jiro' Blurry map backgrounds used in video by: LAz Video edited ...
PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment....
Сообщить об ошибке
Precisamente você estando ganhando do seu inimigo você vai ajudar seu amigo,isso pode lançar uma brecha de modo a este seu inimigo te punir/recuar
gameplay.tips  · The experienced users of that weapon, katars, scyhte's just makes me wants to jump out from a cliff.
This cookie is set by the provider Powr.io. This cookie is used to preserve the user state across the page request.
Cynthia: And get more info then this device will then be readily available in labs throughout different countries that many clinicians can use to test for MRD negativity and positivity. Is that correct?
However, I hope that my statistical-based approach is a good attempt to provide a reliable list for all the casual and ranked players.